drugset / Trial / NCT03007719
Functional Imaging of T-Cell Activation With [18F]F-AraG in Urothelial Carcinoma Patients Receiving Neoadjuvant Therapy or Patients With Cancer Receiving Standard of Care Anti-PD-1/L1
Non-randomizedParallel-groupOpen-labelDiagnostic
Summary
This phase II trial studies how well fluorine F 18 Ara-G positron emission tomography (PET)/magnetic resonance (MR) imaging works in measuring clinical response to atezolizumab or patients with cancer receiving standard of care Anti-PD-1/L1. Diagnostic procedures, such as fluorine F 18 Ara-G PET/MR imaging, may help measure a patient's response to standard of care atezolizumab or Anti-PD-1/L1 treatment.
Timeline
- Start
- 2017-03-07
- Primary completion
- 2019-01-11
- Completion
- 2019-01-11
Outcome
Outcome not reported
Stopped (Enrollment): “Low Accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fluorine F 18 Ara-G | Diagnostic / imaging agent | — | Intravenous |